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Abstract
Sentinel lymph node biopsy (SLNB) is a standard procedure for regional lymph node staging and still has the most important
prognostic value for the outcome of patients with thin melanoma. In addition to ulceration, SLNB had to be considered even for a
singlemitotic figure in thin (<1 mm)melanoma according to AJCC7th guideline, therefore, a retrospective reviewwas conducted
involving 403 pT1 melanoma patients. Among them, 152 patients suffered from pT1b ulcerated or mitotic rate ≥ 1/ mm2
melanomas according to the AJCC7th staging system. SLNB was performed in 78 cases, of which nine (11.5%) showed SLN
positivity. From them, interestingly, we found a relatively high positive sentinel rate (6/78–8%) in the case of thin primary
melanomas ˂0.8 mm. Moreover, the presence of regression increased the probability of sentinel positivity by 5.796 fold. After
reassessing pT stage based on the new AJCC8th, 37 pT1b cases were reordered into pT1a category. There was no significant
relation between other characteristics examined (age, gender, Breslow, Clark level, and mitosis index) and sentinel node posi-
tivity. Based on our data, we suggest that mitotic rate alone is not a sufficiently powerful predictor of SLN status in thin
melanomas. If strict histopathological definition criteria are applied, regression might be an additional adverse feature that aids
in identifying T1 patients most likely to be SLN-positive. After reassessing of pT1b cases according to AJCC8th regression
proved to be independent prognostic factor on sentinel lymph node positivity. Our results propose that sentinel lymph node
biopsy might also be considered at patients with regressive thin (˂0.8 mm) melanomas.
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Introduction
Although accounting for less than 5% of skin cancers, malignant
melanoma is responsible for 80% of skin cancer-related deaths,
and its incidence is increasing worldwide [1]. Because of in-
creased awareness and earlier diagnosis, approximately 80% of
new cases are in situ or early invasivemelanomas. The prognosis
for these patients is relatively good, with ten-year survival rates
of more than 90% [2–4].
The result of the Multicentre Selective Lymphadenectomy
Trial (MSLT-I) has been published, confirming the previous prac-
tice of performing sentinel lymph node biopsy (SLNB) in the
case of intermediate and thick melanomas [5]. However, some
authors already argue with the result or interpretation [6],
highlighting some questionable points of the trial and debating
the real benefit of the SLNB to ten-year melanoma-specific sur-
vival. The predictive role of sentinel lymph node positivity in
thin melanoma has been investigated and reported by several
authors [7–11]. There is a consensus in the literature that the
metastatic involvement of regional lymph nodes is still one of
the most important prognostic factors of thick and thin cutaneous
melanomas as well, however, the criteria and the indications of
thin melanomas for SLNB are inconsistent and the results both
contradictory and incoherent [12].
In 2009, the American Joint Committee on Cancer (AJCC)
published the 7th edition of the staging system for melanomas
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which relies on thickness, ulceration and mitotic rate in the
dermis. According to AJCC7th recommendation, SLNB
should be considered in the case of melanomas ≤1 mm in
thickness, with ulceration or with even a single mitotic fig.
[4]. The local guidelines for thin melanomas were modified at
our department in early 2011 and the AJCC7th adopted, as
SLNB was offered not only if ulceration was present but if
mitotic rate ≥ 1/mm2 of the tumour area. According to the new
AJCC8th guidelines, dermal mitoses are not considered for
pT1b, however, mitotic activity should be noted as indepen-
dent prognostic factor [13].
In our retrospective study, we aimed to investigate the pre-
dictive value of mitotic rate and to analyse further clinicopath-
ologic predictors of positive SLNB by examining the common
feature of these metastasizing cases in order to prevent the
majority of the T1b melanoma patients from undergoing
SLNB. Cases were also reassessed according to the AJCC8th
guideline and additional statistical analyses were performed to
re-evaluate the prognostic value of the well-known histologi-
cal parameters considering AJCC8th.
Patients and Methods
The Department of Dermatology and Allergology,
University of Szeged, is a regional centre for the manage-
ment of cutaneous malignancies, being responsible for
melanoma care for the 1.5 million inhabitants of south-
eastern Hungary. A retrospective review was conducted
involving patients treated at our department with thin mel-
anomas (˂1 mm) between January 2011 and December
2014 (Ethical approval: MEL-RETRO-001; number:
3521, 40/2015). During these four years, 625 consequtive
primary melanomas were diagnosed at our department.
Four hundred and three pT1 melanoma patients entered
our study; among these cases, 152 patients suffered from
pT1b ulcerated or mitotic rate ≥ 1/mm2 melanomas ac-
cording to the AJCC7th staging system. We also planned
to evaluate the common and characteristic features of pri-
mary melanomas among thin melanoma cases with senti-
nel node involvement. On the basis of the histopatholog-
ical results of the primary tumours, a multidisciplinary
tumour board approved a therapeutic plan and the choice
of SLNB was discussed with patients in all cases. SLNB
was offered to most eligible patients with pT1b melano-
mas as part of their surgical management in the absence of
clinically evident nodal disease, or known distant metas-
tases. SLNB was not advised if any sign of dissemination
was detected in the case of high biological age, severe
comorbidities or pregnancy. Some patients had declined
surgery. Seventy-eight cases of SLNB were included in
the study based on the criteria which are listed below.
Histopathology
A standardized histopathological examination was performed on
samples of primary melanoma, re-excision and sentinel lymph
node dissection. Specimens were fixed in 4% buffered formal-
dehyde embedded in paraffin, and 4 μm sections were placed on
silanized slides. In addition to routine haematoxylin eosin stain-
ing (Leica ST5020), further immunohistochemistry (Leica Bond
Max Autostainer) involved Melan-A (DAKO; mouse clone
A103), HMB45 (Biocare; mouse monoclonal), and occasionally
S100 (DAKO, rabbit monoclonal) antibodies in a dilution of
1:300, 1:200, and 1:2000, respectively. At least three serial sec-
tions were prepared from sentinel node specimens.
Surgical Procedure
Sentinel lymph node biopsy (SLNB) for the staging of melano-
ma was first described in detail in 1992. We perform combined
radiotracer and blue dyemapping as usual. On the day before the
surgery, dynamic lymphoscintigraphy is performed with human
albumin colloid (Sentiscint; FJC Institute, Budapest, Hungary,
Medi-Radiopharma Ltd., Érd, Hungary) labelled with 99mTc
pertechnetate, with 80% of the particles sized 100 to 600 nm.
As part of the double staining, 0.5 to 2.0 ml vital blue dye (Byk-
Gulden, Konstanz, Germany) is injected 15–20 min before the
incision. During the operation, a handheld gamma probe (C-
Trak, AEA Technology, Darwin House, Birchwood Park,
Warrington and Navigator GPS System; RMD Instruments
Corp. Watertown, MA 02472 USA) is used to identify the hot
spots. The nodes with significant activity or with vital blue stain
are considered sentinel lymph nodes. The radiotracer activity of
these nodes is measured ex vivo and compared to the bed from
which they were removed. A radioactive lymph node is defined
as positive and removed until the background counts are <10%
of the hottest node removed. If the postoperative histology re-
veals metastasis in the lymph nodes, completion lymph node
dissection is offered to the patient.
Statistical Methods
The SLN positivity rate was the primary outcome. The clinico-
pathological features analysed were age, sex, melanoma type,
location, ulceration, Breslow thickness, Clark level, mitotic rate,
regression, and SLN status. The relationships between SLN pos-
itivity and each of the clinical and histopathological parameters
were assessed with Chi-square test, Student’s t test and Fisher’s
exact test. Potential risk factors for SLNmetastasis were analysed
bymultivariate logistic regression models with the enter method,
and odds ratios (OR) and 95% confidence intervals (CI) were
calculated for categorical variables. The predictive value of the
multivariate logistic regression model was measured with the
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Nagelkerke R Square method. The relationship between the re-
evaluated pT stage and the SNL status was assessed by Mann
WhitneyU test.P values <0.05were considered to be statistically
significant and all p values were two-sided. All statistical analy-
ses were performed with the IBM SPSS Statistics Version 23.0
program.
Results
According to AJCC7th 152 patients with pT1b melanoma en-
tered our study. Among these 152 cases, 74 patients underwent
only local wide excisionwith a 1 cm safetymargin. In addition of
local wide excision SLNB was also performed in 78 cases.
Twelve patients were excluded for previous cutaneous or other
malignancies; the remaining patients were not involved due to
high biological age, severe comorbidities or pregnancy, or be-
cause they had s imply dec l ined the procedure .
Lymphoscintigraphy successfully identified the draining lym-
phatic basin and sentinel node in all 78 patients. The majority
of patients were sentinel node-negative (n = 69); in nine cases
(11.5%) metastasis was detected in the regional lymph nodes.
The location, Clark level and mitotic rate of the tumour, the
presence of ulceration, and regression were examined and com-
pared. Complete lymph node dissection (CLND) was performed
in 7/9 positive SLN cases. Additional metastatic LNswere found
in two cases.
Site of the Primary Tumour and SLN
With regard to the location of the primary melanoma, the
majority of these tumours were found on the lower extremities
in women and on the trunk in men, as we expected (Table 1).
Among patients who underwent SLNB, the most frequent
location of the primary tumours was the dorsal region of the
trunk (27/78 overall, 14/34 in men and 13/44 in women);
however, a high proportion of the tumours were located on
the lower limbs in the women (16/44). In our series, the SLN
positivity was independent of the location of the primary tu-
mour (Fisher’s exact test p = 0.9312).
As regards the location of the sentinel nodes, 46 patients
had axillary SLNB, in seven cases from both sides. Six of these
46 patients had metastatic lymph nodes. Three patients had
sentinel nodes from both the axillary and inguinal regions;
one of these patients had a positive sentinel node. In 22 cases,
the nodes were removed from the inguinum (1 positive) and in
the case of two patients from the popliteal region as well (1
positive). Four patients had sentinel nodes in the neck, and one
patient had a sentinel node at an atypical site (over the scapula).
Age and Gender
The overall male/female ratio was 1:1. Of the patients who
underwent SLNB, 43.5% were male, and the median age was
48.5 years (range 20–77 yrs). The onset of melanoma diagnosis
did not differ significantly in the node-negative (48.8 yrs) and
node-positive (46.3 yrs) groups. However, the mean age with
pT1b/nodal involvement was 58.2 and 31.5 years among men
and women, respectively. Moreover, in the younger age group
(<35 yrs) the SLN positivity rate was 22.2%, which is higher
than the average in all cases. Demographic and histopathological
characteristics of the SNLB group are shown in Table 2.
Multivariate logistic regressionmodelling demonstrates the
association between SLN positivity and age, gender, Breslow,
Clark level, and regression. The presence of regression in the
primary tumour increases the probability of sentinel positivity
by 5.796-fold. There was a significant correlation noted be-
tween histological regression and sentinel lymph node posi-
tivity, however, no significant relation between the other char-
acteristics examined (age, gender, Breslow, Clark level, mito-
sis index; Nagelkerke R square = 0.7). After reassessing the
pTstage according to the AJCC8th guideline, 37 patients were
reclassified from pT1b into pT1a category. By repeating the
statistical analyses there was no significant association be-
tween reclassified stage and SLN positivity indicating that
regression may have independent prognostic value on the
lymphatic spread of melanoma (Table 3).
Discussion
SNB has become standard procedure for the staging of the
regional nodal basin in patients diagnosed with thin melanoma
and remains one of the most important predictive factors of the
Table 1 Location of primary tumours among all patients and in the SLNB group
Location Overall male (n = 75) Overall female (n = 77) SLNB male (n = 34) SLNB female (n = 44)
Head and neck 5 5 3 1
Trunk ventral 10 12 4 7
Trunk dorsal 33 21 14 13
Upper extremity 19 16 8 6
Lower extremity 7 22 4 16
Acral 1 1 1 1
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outcome for these patients [7–11]. However, Morton et al. re-
ported that local complications occur in approximately 10% of
SNBs, a percentage which is not higher than other elective,
clean surgeries [14]. Several previous authors have attempted
to identify predictive risk factors for nodal metastases in thin
melanomas, including Breslow thickness, ulceration,
regression, Clark level, age, and tumour-infiltrating lympho-
cytes to prevent overtreatment of these patients. However, no
widely accepted consensus exists as to which patients are at
risk for nodal metastases.
In our study, we aimed to assess how efficiently melanoma
staging systems can predict the occurrence of nodal metastases
Table 2 Demographic and histological characteristics of the primary tumours with SLNB
Variable All patients with SLNB SLN-positive SLN-negative p value OR
Total no. 78 9 69
Age mean (years) 48.526 46.33 48.812 0.614b
<35 18 4 14 0.136a
36–49 21 0 21
50–64 32 4 28
>65 7 1 6
Gender 0.492a 1.724 (0.426–6.985) c
Male 34 5 29
Female 44 4 40
Histological type
Superficial spreading 72
Nodular 4
Acral lentiginosus 2
Location 0.9312 a
Head and neck 4 0 4
Trunk ventral 11 2 9
Trunk dorsal 27 4 23
Upper extremities 14 1 13
Lower extremities 20 2 18
Acral 2 0 2
Thickness (mean) 0.716 0.714 0.717 0.966b
Ulceration 0.586 a 0c
Present 8 0 8
Absent 70 9 61
Mitotic rate (mean) 2.25 1.89 2.29 0.494 b
Clark level 0.715 a 1.5 (0.368–6.114) c
II 28 4 24
III 50 5 45
Regression 0.044 a 4 (0.916–17.459) c
Present 29 6 23
Absent 49 3 46
Reclassified stage (AJCC8th) 0.566 d
pT1a 37 4 33
pT1b 41 5e 36
a Fisher’s exact test
b Student t-test
c OR (95% CI)
dMann Whitney U
e Two patients had melanoma with Breslow 0.76 mm, less than 0.8 mm, but ordered into pT1b group
α = 0.05
p two-sided
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in thin melanoma and whether there are any other additional
criteria to improve this rate.
Age and Gender
Younger patient age is associated with a higher nodal metas-
tasis rate among melanoma patients in general [3, 11, 15–18];
however, the available studies in thin melanoma are inconsis-
tent on this factor, and there is no widely accepted specific age
cut-off value under which SLNB should be performed.
Kretschmer et al. reported that young patients (<40 years) in
a series of 0.75–1.00 mm thin melanoma patients had a sig-
nificantly higher SLN positivity rate than older age groups
[19]. Sondak et al. have also reported that relatively young
age (besides MR and Breslow depth) is associated with posi-
tive SLNs in melanoma patients [16]. In our study, we did not
apply a particular cut-off age for SLNB (range 20–77 years).
We placed emphasis on the characteristics of the tumour rather
than on comorbidities or biological age. Corresponding to
findings by Balch et al., male patients were slightly older than
female patients (49.5 vs. 47.7 yrs.) [20]. However, our study
did not identify any significant difference with regard to age
among the SLN-positive and -negative groups. On the other
hand, a marked difference was observed between male and
female patients with metastatic SLNs. The mean age of
SLN-positive men was 58.2 years versus 31.5 years among
women. This might be the result of the small sample size of
patients involved, and further investigation may be required.
Breslow Thickness
The thickness of melanoma is generally considered the most
useful prognostic factor in patients with thin melanoma. In a
study of 121 thin melanoma cases, Hinz et al. [8] found that all
SLN-positive patients belonged to the subgroup of tumour
thickness range 0.9–0.99 mm. Han et al. [21] reported that a
Breslow thickness of ≥0.76 mm is associated with a 4.9–
12.8% rate of SLN metastases. However, according to these
studies, only 0–2.3% of melanomas ˂0.76 mm is associated
with nodal disease. Our results are similar for thin melanomas
<1 mm (11.5%) but we have found a relatively high positive
sentinel rate (8%) for primary melanomas ˂0.8 mm. While
Murali et al. [15] reported that patients with thin melanomas
of <0.50 mm have negative SLN stage, Bagaria et al. reported
that melanomas of <0.50 mm are identified as a factor of
worse prognosis in term of SLNmetastases [22]. In our series,
1/9 cases of primary melanoma ˂0.50 mm had nodal metas-
tasis. Interestingly, corresponding to results by Mitteldorf
et al. [9], we found no significant difference in sentinel nodal
metastases between the ˂0.76 mm and the 0.76–1.00 mm
groups.
Ulceration
According to the latest two AJCC Melanoma Staging and
Classification schemes, thin melanomas continue to be classi-
fied as T1b by the presence of ulceration [4, 13]. Several
studies have reported that ulceration is a rare event (1–15%)
in thin melanomas [3, 23–25]. In our series, only 12 melano-
mas were ulcerated among the 152 pT1 tumours (7.9%). In the
group of patients that underwent SNB, 8/78 primary tumours
(10%) showed ulceration. In their study of 147 thin melanoma
patients, Yonick et al. found that ulceration (and Breslow
thickness) was an independent predictor of nodal disease
[26]. A study of 77 patients by Oliveira Filho et al. confirmed
this result [27]. However, most studies have not shown ulcer-
ation as a significant predictor [10, 11, 15, 26, 28–30].
Kesmodel et al. reported that 181 thin melanoma patients with
positive SLNs showed no signs of ulceration in the primary
tumour [28]. Our results are consistent with these findings.
None of the primary thin melanomas showing ulceration had
nodal metastasis.
Mitotic Rate
Mitotic rate (MR) is defined as themaximum number of dermal
mitoses per mm2. According to the staging system for melano-
mas in the AJCC7th edition, even a single mitosis can be cate-
gorized as T1b in the case of a small dermal tumour area, and,
therefore, SLB should be considered [4, 31]. However, with
only one mitotic figure being the cut-off point, this method
may be unreliable even with an additional immunohistochem-
istry [32]. Several authors have reported that primarymelanoma
mitoses predict SLN status [10, 16, 28]. Furthermore, Sondak
et al. have found young patients (<35 years) that showed anMR
correlation with a positive SLN. Interestingly, this was not the
case with Breslow thickness [16]. Other studies showed no
such association, even revealing that up to one-third of SLN-
Table 3 Multivariate logistic regression model of the clinicopathologic
parameters
Multivariate logistic
regression model
SLN positivity
Variable OR (95% CI) p
Age .958 (.916; 1.002) 0.059
Gender .651 (.152; 2.782) 0.562
Breslow 1.626 (.036; 72.656) 0.802
Clark .560 (.112; 2.807) 0.480
Mitosis index .723 (.348; 1.502) 0.385
Regression 5.796 (1.046; 32.123) 0.044 *
OR odds ratio
CI confidence interval
*p < 0.05 significant
method = enter
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positive thin melanomas have zero mitosis [3, 15, 33]. In our
study, there was no observable significance in mitotic rate be-
tween the node-positive and -negative group (Student t-test; t =
−0.688; df = 76; p = 0.494).
Regression
The clinical significance of clinical and histological regression
in melanoma is still debated, with numerous studies reporting
a higher rate of metastasis in thin, regressed melanomas [34,
35]. In our previous study [30], we also found that tumour
regression predicts a higher risk of sentinel node involvement
in melanomas ˂2.0 mm in a series of 134 melanoma patients.
Other authors showed no association with recurrence or sur-
vival [18, 36]. This contradiction could be explained in part
with the lack of a uniform definition for regression. Without
these uniform criteria, the reproducibility of the results may be
difficult. At our department, we used the criteria suggested by
the Pathological Group of the World Health Organization
Melanoma Programme for the definition of regression. This
includes the presence of a zone of tumour-free epidermis and
dermis in which there is fibrosis, often along with inflamma-
tion and dilated vessels, flanked on one or both sides by a
tumour (Fig. 1). These criteria for regression are also involved
in the study by Botella-Estrada et al. [37] regarding (i) de-
crease or absence of melanoma cells in the dermal component
of the tumour, presence of (ii) fibrosis, (iii) inflammatory in-
filtrate, (iv) melanophages, (v) neovascularization, (vi) epider-
mal flattening and (vii) keratinocytic/melanocytic damage.
Features (i–v) together are considered obligatory elements
for the diagnosis of regression. The extension of regression
was horizontally evaluated and divided into focal or main
categories; the cut-off point was a percentage of 75% in the
horizontal extension of primary melanoma.
In our recent study using univariate and multivariate logis-
tic regression analysis, regression turned out to be the only
significant independent predictor of SLN metastases (OR =
5.796). These results confirm our previous findings that
Fig. 1 shows a case report of a male patient aged 71, presenting
regressing superficial spreading melanoma on his back region (a). At
dermoscopy, the centre of the polychrome plaque displayed greyish-
whitish area with peppering sign which is characteristic for regression
(b). After the surgical removal of tumour, the histopathology showed
extensive vanishing of junctional and dermal melanoma cells replaced
by fibrosis, accumulation of melanophages and lymphocytic infiltrate
together with focal neovascularisation (c - circumscribed faded area).
Only the edges of the presented section contained atypical residual
microinvasive melanoma cells within the regressive microenvironment.
Although calculated Breslow thickness from the residual melanoma
counterpart showed only 0.532 mm, dermal mitotic activity together with
the adverse regression indicated SLNB. During the histopathological pro-
cessing right axillary SLN contained scattered metastatic melanoma cells
(d) which were also present in two other lymph nodes in the right axillary
dissection sample (e)
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patients with Breslow <2.0 mm but regressing melanomas
have a four-time higher relative risk of developing nodal me-
tastases than patients with non-regressing melanomas. This
may verify our previous hypothesis that histological regres-
sion can result in a decreased Breslow thickness measurement
and thus in some cases an erroneously more favourable prog-
nostic estimate. In contrast, the overvaluation of early regres-
sion signs may also result in false regression data for statistical
analyses.
Conclusion
According to the large, multicentre studies, thin melanomas
(<1.00 mm) have a low, but significant risk for SLN metasta-
ses; however, these studies often apply various criteria for
staging and performing SNB. Prospective standardized
multicentre trials with standardized clinicopathologic and de-
mographic criteria for performing SNB in thin melanomas are
needed to specify widely accepted, reliable predictors.
Compared to the numerous multicentre-studies published
recently, the benefit of our results may be the uniform criteria
for diagnosis and treatment, as all the cases were managed at a
single institution, with uniform surgical techniques and stan-
dard histology protocols for processing and evaluating prima-
ry melanomas and SLNs.
Our analysis support the recent AJCC8th classification
that mitotic rate alone is not a sufficiently powerful pre-
dictor of SLN status in thin melanomas. If strict histopath-
ological definition criteria are applied, regression might
be an additional adverse feature that aids to identifying
those T1 patients most likely to be SLN-positive, there-
fore sentinel lymph node biopsy might be considered in
the case of patients with widely regressive thin (˂0.8 mm)
melanomas.
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